Atea Pharmaceuticals (AVIR) Accounts Payables (2020 - 2022)
Historic Accounts Payables for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $1.1 million.
- Atea Pharmaceuticals' Accounts Payables fell 9496.17% to $1.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.1 million, marking a year-over-year decrease of 9496.17%. This contributed to the annual value of $4.5 million for FY2021, which is 745666.67% up from last year.
- Per Atea Pharmaceuticals' latest filing, its Accounts Payables stood at $1.1 million for Q3 2022, which was down 9496.17% from $13.9 million recorded in Q2 2022.
- In the past 5 years, Atea Pharmaceuticals' Accounts Payables ranged from a high of $22.2 million in Q3 2021 and a low of $60000.0 during Q4 2020
- In the last 3 years, Atea Pharmaceuticals' Accounts Payables had a median value of $4.5 million in 2020 and averaged $7.2 million.
- Per our database at Business Quant, Atea Pharmaceuticals' Accounts Payables surged by 745666.67% in 2021 and then plummeted by 9496.17% in 2022.
- Quarter analysis of 3 years shows Atea Pharmaceuticals' Accounts Payables stood at $60000.0 in 2020, then surged by 7456.67% to $4.5 million in 2021, then tumbled by 75.34% to $1.1 million in 2022.
- Its Accounts Payables stands at $1.1 million for Q3 2022, versus $13.9 million for Q2 2022 and $3.7 million for Q1 2022.